Back to Search
Start Over
Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors
- Source :
- ACS Nano
- Publication Year :
- 2022
-
Abstract
- The generation of specific humoral and cellular immune responses plays a pivotal role in the development of effective vaccines against tumors. Especially the presence of antigen-specific, cytotoxic T cells influences the outcome of therapeutic cancer vaccinations. Different strategies, ranging from delivering antigen-encoding mRNAs to peptides or full antigens, are accessible but often suffer from insufficient immunogenicity and require immune-boosting adjuvants as well as carrier platforms to ensure stability and adequate retention. Here, we introduce a pH-responsive nanogel platform as a two-component antitumor vaccine that is safe for intravenous application and elicits robust immune responses
Details
- ISSN :
- 1936086X
- Volume :
- 16
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- ACS nano
- Accession number :
- edsair.doi.dedup.....6e9f646debac17e75bfa479e6d5a1492